夏橘化瘀胶囊对冠心病患者经皮冠状动脉介入治疗后支架内再狭窄及血清炎性因子水平的影响研究  

Impact of Xiaju Huayu Capsule on In-stent Restenosis and Serum Inflammatory Cytokines Levels in Postoperative Coronary Heart Disease Patients Treated by PCI

作　　者：金子安 李杰[1] 陈阳 JIN Zi-an;LI Jie;CHEN Yang(Department of Cardiovascular Disease,the Traditional Chinese Medicine Hospital of Weifang,Weifang 261041,China)

机构地区：[1]山东省潍坊市中医院心血管病科,261041

出　　处：《实用心脑肺血管病杂志》2018年第7期82-85,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：2018年潍坊市中医药科研立项项目(20184018)

摘　　要：目的探讨夏橘化瘀胶囊对冠心病患者经皮冠状动脉介入治疗(PCI)后支架内再狭窄及血清炎性因子水平的影响。方法选取2015年6月—2017年6月在潍坊市中医院行PCI的冠心病患者68例,采用随机数字表法分为对照组和治疗组,每组34例。两组患者入院后均行PCI并给予常规对症治疗,治疗组患者在此基础上加用夏橘化瘀胶囊;两组患者均连续治疗12个月。比较两组患者PCI后12个月心绞痛发生率、支架内再狭窄发生率,PCI前及PCI后3 d、12个月血清炎性因子水平,并观察两组患者治疗期间不良反应发生情况。结果对照组、观察组患者各脱落4例。PCI后12个月治疗组患者心绞痛发生率、支架内再狭窄发生率低于对照组(P<0.05)。PCI前、PCI后3 d两组患者血清生长分化因子15(GDF-15)、超敏C反应蛋白(hs-CRP)、淀粉样蛋白A(SAA)水平比较,差异无统计学意义(P>0.05);PCI后12个月治疗组患者血清GDF-15、hs-CRP、SAA水平低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论夏橘化瘀胶囊能有效降低冠心病患者PCI后心绞痛发生率、支架内再狭发生窄率及血清GDF-15、hs-CRP、SAA水平,且安全性高。Objective To investigate the impact of Xiaju Huayu capsule on in-stent restenosis and serum inflammatory cytokines levels in postoperative coronary heart disease patients treated by PCI.Methods A total of 68 coronary heart disease patients undergoing PCI were selected in the Traditional Chinese Medicine Hospital of Weifang from June 2015 to June 2017,and they were divided into control group and treatment group according to random number table,each of 34 cases.Patients in the two groups received PCI and conventional symptomatic treatment after admission,while patients in treatment group received extra Xiaju Huayu capsule;both groups continuously treated for 12 months.Incidence of angina pectoris and instent restenosis 12 months after PCI,serum inflammatory cytokines levels before PCI,3 days and 12 months after PCI were compared between the two groups,and incidence of adverse reactions was observed during treatment.Results In this study,4 cases in control group and 4 cases in treatment group lost to follow up.Incidence of angina pectoris and in-stent restenosis in treatment group was statistically significantly lower than that in control group 12 months after PCI,respectively(P<0.05).No statistically significant differences of serum level of GDF-15,hs-CRP or SAA was found between the two groups before PCI or 3 days after PCI(P>0.05),while serum levels of GDF-15,hs-CRP and SAA in treatment group were statistically significantly lower than those in control group 12 months after treatment(P<0.05).No statistically significant differences of incidence of adverse reactions between the two groups.Conclusion Xiaju Huayu capsule can effectively reduce the risk of angina pectoris and in-stent restenosis in postoperative coronary heart disease patients treated by PCI,reduce the serum levels of GDF-15,hs-CRP and SAA,with high safety.

关 键 词：冠心病 经皮冠状动脉内介入治疗 夏橘化瘀胶囊 炎性因子 支架内再狭窄 

分 类 号：R541.4[医药卫生—心血管疾病]